Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart TagsBone & JointCardiovascularCatDogEfficacyExotic PetNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Clinical study of PCSO-524 (ANTINOL™) as neutraceutical in canine allergic skin disease
This study included 31 allergic dogs with chronic pruritis with other skin diseases excluded.
Dogs were split into 3 treatment groups based on degree of pruritis, distribution, extension of the lesions and skin and coat condition; Group 1: mild, Group 2: moderate, and Group 3: severe.
All dogs received PCSO-524 loading dose 10 mg/kg q12hr PO for 2 weeks followed by a maintenance dose of 10 mg/kg q24hr PO.
All dogs were evaluated at 2, 4, 8, 12 and 16 weeks for clinical response. The assessment made by the owners (PVAS Score) and Vets (CADESI-03 score).
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted